Idor­sia touts new sleep drug da­ta ahead of PhI­II; Tetraphase out to raise $65M

Acte­lion spin­out Idor­sia says it scored pos­i­tive da­ta from two Phase II stud­ies of a new sleep drug called ACT-541468. In­ves­ti­ga­tors say that they de­signed this drug with two key fea­tures in mind: keep peo­ple asleep through the night with few lin­ger­ing side ef­fects af­ter they wake up. They test­ed the drug in 418 pa­tients, re­port­ing on top-line re­sults. And now the com­pa­ny plans to move in­to Phase III. “I am de­light­ed to see that the pos­i­tive read­outs from this com­pre­hen­sive Phase 2 pro­gram are con­sis­tent with our pre­clin­i­cal pre­dic­tive mod­els, for both adult and el­der­ly pa­tients with in­som­nia,” said CSO Mar­tine Clozel.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.